Please rate:

Hospira (HSP) FDA Approval Gemcitabine Injection

Thank you for joining us. I am your host Sara Bryant at CRWE Newswire Stocks to watch. Hospira, Incorporated - symbol HSP - reported U.S. Food and Drug Administration approval of gemcitabine injection, a solution form of the drug. The solution presentations include 200 mg, 1 gm and 2 gm with a concentration of 38 milligram per milliliter. Hospira is the first company to offer gemcitabine in a solution formulation for the U.S. market. The solution formulation is designed to improve pharmacist convenience and handling safety. The oncology medication had U.S. sales of more than $750 million in 2010, led by Eli Lilly’s Gemzar. Hospira expects to launch the product in early September. Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness. Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Sara Bryant.

Show Description Hide Description